

Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam

Barcelona, March 18th, 2012. Oryzon a Biopharmaceutical company dedicated to the discovery of biomarkers and development of novel therapeutics and diagnostics announced today that Dr. Carlos Buesa, will be present at BioEurope-Spring to pursue Oryzon's ongoing contacts with the industry on March 19-21 at the Amsterdam RAI Convention Center.

Barcelona, March 18th, 2012.

Amsterdam will host this year one of the largest biotech partnering conferences: BioEurope-Spring with 1302 Companies represented by more than 2000 Delegates. Dr. Carlos Buesa, CEO of the company, will attend the meeting to continue the current ongoing contacts with the rest of the industry.

Oryzon was presenting recently its advances on its epigenetic therapeutic program in LSD1 inhibitors in a specialized meeting, the 4th Annual CHI X-Gen Congress, in the CLINICAL GENOMICS. Epigenetics, Targets and Therapies in San Diego, California. Also recently, the company announced that it was entering preclinical development with its first drug candidate, a first-in-class bispecific Lysine Specific Demethylase 1 (LSD1) and Monoamine oxidase B (MAO-B) inhibitor for the treatment of Huntington disease (HD). Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach \$2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.

But also the company will communicate the first steps of the commercial implementation in the Spanish market of its first marketed product: GynEC®-DX, a Non Invasive Diagnostic product consisting on a signature of 5 genes, that are differentially expressed and highly accurate to determine cancer status in uterine aspirates.

Dr. Buesa, CEO of ORYZON said "We are very excited to join again the biotech community in Amsterdam. The innovative imprinting of the biotech industry needs to create win-win relationships with our pharma partners to deliver better healthcare outcomes for patients.

Oryzon has a tight schedule to interact with relevant companies regarding the key programs of the company". The company has an intense agenda and will be present in several specialized meetings in the next months.

About Oryzon

Founded in 2000, Oryzon (www.oryzon.com) has one of the most complete technological platforms for biomarker identification in Europe. With a strong specialization in genomics, proteomics and bioinformatics, the company identifies biomarkers for a variety of neoplastic and neurodegenerative diseases. The company has a powerful platform for biomarker and target validation which includes technologies such as RNAi, microarrays, phage display and a structural genomic platform with a fragment screening approach (NMR and X ray crystallography). Oryzon develops new drugs and monoclonal antibodies against targets identified in its biomarker discovery programs but also develops diagnostic products.

GynEC®-DX is a good example of the Diagnostic activity of the company. This product was discovered after 5 years of intense research. It is a signature of 5 genes differentially expressed that are highly accurate to determine cancer status in uterine aspirates and when combined with pathology on aspirates has a Negative predictive value of 99,6% according to the results obtained in a recent multi-centric double blind prospective study. Commercialization of this product that has been developed jointly with Laboratorios Reig-Jofré is expected in 1Q 2012.

Other launches under way

Oryzon entered into a partnership in the field of molecular diagnostics with New Zealand firm Pacific Edge Ltd in 2011. According to the agreement, Oryzon holds an exclusive license to market the Cxbladder assay, which detects bladder cancer in urine in some European countries. Oryzon will run the Cxbladder test in its Clinical Analysis Lab, which was authorized by the Catalanian Government last year. *"The central lab is the axis and launching platform of our diagnostic and personalized medicine division",* explains Carlos Buesa. *"We have shown that our biomarker discovery platform is capable of developing personalized medicine products and bringing them to market. The goal is to become the leader in molecular diagnostics in Spain and to partner our therapeutic programs with specialized pharmaceutical companies."*

For further information, please contact:

Carlos Buesa
Chief Executive Officer
Tel. +34 93 515 13 13,
cbuesa@oryzon.com

Emili Torrell
Business Development Officer
Tel. +34 93 515 13 13,

etorrell@oryzon.com